Niche-targeted therapies offer a fresh approach to regenerative medicine

A healthy bone marrow (BM) produces nearly all types of cells in our blood. Many blood disorders occur when hematopoietic stem cells (HSCs) in the BM malfunction. Many blood disorders and cancers are treated with radiation or chemotherapy, which as a side effect depletes not only tumor cells but also hematopoietic cells including HSCs in the BM-a condition known as myelosuppression.
In severe cases, HSC transplantation (HSCT) is required to restore hematopoiesis. The BM niche is a complex environment comprising supporting cells such as endothelial cells (ECs) and mesenchymal stromal cells (MSCs) that sustain HSC activity. These cells are also damaged during myeloablative therapies, and their poor recovery can lead to reduced chemotherapy and HSCT efficacy. However, the mechanisms underlying the BM niche recovery remain elusive, and therapeutic strategies targeting niche recovery are underdeveloped.
To address this, a team of researchers led by Professor Atsushi Iwama from The Institute of Medical Science, The University of Tokyo, Japan, along with Dr. Shun Uemura from The Institute of Medical Science, The University of Tokyo, Japan, Dr. Masayuki Yamashita from St. Jude Children's Research Hospital, USA, and Dr. Taito Nishino from Nissan Chemical Corporation, Japan, conducted a study to define the role of two transcriptional co-activators YAP and TAZ in the BM niche during regenerative hematopoiesis, as well as to assess the therapeutic potential of YAP/TAZ activation. Their findings were published in the journal Blood on June 22, 2026.
The team generated a series of mouse models where YAP/TAZ genes had been knocked out specifically in either ECs, MSCs, or hematopoietic cells. Under steady-state conditions, mice with YAP/TAZ knockout in MSCs showed reduced HSC numbers in the BM and increased HSC mobilization into circulating blood, demonstrating that basal YAP/TAZ activity in MSCs is essential for retaining HSCs in the BM. By contrast, YAP/TAZ in hematopoietic cells was found to be largely dispensable under both steady-state and post-injury conditions.
When exposed to radiation, hematopoietic recovery was significantly impaired in mice with YAP/TAZ knockout in MSCs, while loss of YAP/TAZ in ECs led to pronounced blood vessel dilation, indicating that YAP/TAZ in both MSCs and ECs plays a critical role in BM niche recovery after injury. Mechanistically, YAP/TAZ regulates key transcription factors such as Ebf1 and Ebf3 in MSCs, preserving MSC identity and promoting the expression of hematopoietic factors such as Cxcl12 and angiogenic factors.
In addition, YAP/TAZ in MSCs and ECs coordinately remodel sinusoidal vessels following BM injury. Overall, these YAP/TAZ-mediated niche responses are essential for hematopoietic regeneration following myeloablative therapies.
The researchers also identified a small molecule called GA-003 which inhibits LATS1/2 kinase and increased YAP/TAZ activity. When mice were given GA-003 after radiation, BM niche recovery was significantly enhanced and hematopoietic regeneration was accelerated. GA-003 also promoted engraftment following HSCT and acted synergistically with granulocyte colony-stimulating factor, a drug commonly used to treat neutropenia, to further enhance white blood cell recovery.
Our study may have significant impact by introducing a new therapeutic concept that targets the BM niche rather than hematopoietic cells themselves. It may stimulate further studies on microenvironment-driven regeneration involving similar signaling pathways in tissues."
Atsushi Iwama, Professor, The Institute of Medical Science, The University of Tokyo
To summarize, the identification of pharmacological YAP/TAZ activation as a viable strategy provides a foundation for future drug development targeting tissue niches, potentially expanding research into niche-targeted therapies across regenerative medicine and disease contexts. It may influence a broad range of research fields by introducing a new conceptual framework that emphasizes the role of the tissue microenvironment in regeneration.
"Our new therapeutic approach addresses the limitation of supportive therapies and enhances the recovery of the BM niche, thereby enabling coordinated restoration of multiple blood cell lineages, including neutrophils, red blood cells, and platelets. This has the potential to improve the overall management of hematopoietic complications associated with chemotherapy, radiotherapy, and HSCT," concludes Prof. Iwama.
Source:
Journal reference:
Uemura, S., et al. (2026) Niche-targeted therapy via YAP/TAZ activation enhances hematopoietic regeneration. Blood Journal. DOI: 10.1182/blood.2025030831. https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025030831/569276/Niche-targeted-therapy-via-YAP-TAZ-activation?redirectedFrom=fulltext

Facts Only

* Healthy bone marrow produces nearly all blood cells.
* Hematopoietic stem cells (HSCs) in the BM malfunction in many blood disorders.
* Radiation or chemotherapy can deplete hematopoietic cells, including HSCs in the BM, causing myelosuppression.
* The BM niche comprises supporting cells like ECs and MSCs that sustain HSC activity.
* YAP and TAZ transcriptional co-activators were studied for their role in the BM niche during regenerative hematopoiesis.
* Knocking out YAP/TAZ in MSCs resulted in reduced HSC numbers and increased HSC mobilization into the blood under steady-state conditions.
* Loss of YAP/TAZ in ECs led to pronounced blood vessel dilation after radiation exposure.
* YAP/TAZ regulates transcription factors like Ebf1 and Ebf3 in MSCs, promoting hematopoietic factor expression (e.g., Cxcl12).
* YAP/TAZ in MSCs and ECs coordinate sinusoidal vessel remodeling following BM injury.
* GA-003, an inhibitor of LATS1/2 kinase, increased YAP/TAZ activity.
* GA-003 enhanced BM niche recovery and accelerated hematopoietic regeneration after radiation and HSCT.

Executive Summary

The study investigated the role of the bone marrow (BM) niche in hematopoietic regeneration following treatments like radiation or chemotherapy, which cause myelosuppression by depleting hematopoietic stem cells (HSCs). The BM niche is maintained by supporting cells such as endothelial cells (ECs) and mesenchymal stromal cells (MSCs), which sustain HSC activity. The research focused on YAP and TAZ, two transcriptional co-activators, in the context of this niche recovery. Experimental models involved knocking out YAP/TAZ specifically in ECs, MSCs, or hematopoietic cells to assess their impact. Findings indicated that basal YAP/TAZ activity in MSCs is necessary for retaining HSCs within the BM. Loss of YAP/TAZ in MSCs impaired hematopoietic recovery after radiation injury, and loss in ECs caused vascular dilation. The study concluded that YAP/TAZ signaling in both MSCs and ECs coordinates sinusoidal vessel remodeling and is essential for hematopoietic regeneration after myeloablative therapies. A small molecule, GA-003, which activates YAP/TAZ by inhibiting LATS1/2 kinase, significantly enhanced BM niche recovery and accelerated hematopoietic regeneration following radiation and supported engraftment after HSCT.

Full Take

The research establishes a framework where the integrity of the tissue microenvironment, specifically the BM niche regulated by YAP/TAZ signaling in stromal cells (MSCs and ECs), is a critical determinant for successful hematopoietic regeneration following systemic insults. The core implication shifts focus from merely restoring blood cell counts to actively healing the supportive tissue environment that governs stem cell retention and function. The finding that manipulating signaling pathways in non-hematopoietic support cells yields system-wide hematopoietic benefits suggests that regenerative medicine should prioritize niche engineering over direct cell manipulation. The successful intervention with GA-003 reinforces the concept of targeting these signaling hubs—YAP/TAZ activation—as a viable, context-specific therapeutic strategy for mitigating systemic damage from therapies like chemotherapy and radiation. This calls into question why previous efforts focused predominantly on hematopoietic cells themselves rather than their regulatory microenvironment. The missing element appears to be an established conceptual framework linking niche mechanics directly to long-term stem cell fate across various regenerative contexts. Future inquiry must focus on whether these YAP/TAZ-mediated responses are conserved mechanisms for tissue regeneration beyond hematopoiesis, and how this concept can be generalized to other organ systems facing damage from systemic therapies.

Sentinel — Human

Confidence

This analysis reports on a published scientific study detailing the role of YAP/TAZ in bone marrow niche recovery following radiation therapy and proposes a novel therapeutic strategy targeting this microenvironment.

Signals Detected

Moderate sentence length variance; appropriate academic rhythm.

Strong flow connecting biological mechanism to experimental results and clinical implications.

Specific citation of named researchers, institutions, and a precise journal reference.

Highly specific molecular pathways (YAP/TAZ, LATS1/2, Ebf1, Cxcl12) and structured experimental findings suggest primary sourcing.

Human Indicators

The text synthesizes highly technical scientific findings, names specific researchers from named institutions, and cites a precise journal reference with a DOI, which is characteristic of reporting on primary research.